-- Dr. Cudkowicz is a pioneer in the study and treatment of people with Amyotrophic Lateral Sclerosis (ALS) and other…
JSP191 is currently being evaluated in four ongoing clinical studies in allogeneic hematopoietic stem cell transplant in patients with Acute…
TORONTO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device…
Facility team in the of the UofL Health - Brown Cancer Center GMP Manufacturing Facility at the University of Louisville.…
P2B001 is a novel proprietary fixed-dose combination of extended-release (ER) formulations of low doses of pramipexole and rasagiline; both doses…
Recent research study demonstrates that the majority of clients experience reliable improvement in symptoms after just two months of treatmentVANCOUVER,…
Cutaneous T-Cell Lymphoma is the second orphan drug designation for KT-333WATERTOWN, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics,…
DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company…
OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022 SIGNIFICANT STRATEGIC AND OPERATIONAL PROGRESS TOWARDS BECOMING A…
Signals of Clinical Benefit Detected in Small Phase 2 Study, Suggesting Potential to Show Statistically Significant Therapeutic Benefit in Larger,…